NCT06144918View on ClinicalTrials.gov

Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

February 22, 2024

Study Completion Date

February 22, 2024

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

SBI-100 Ophthalmic Emulsion, 0.5%

0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop

DRUG

SBI-100 Ophthalmic Emulsion, 1.0%

1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop

DRUG

SBI-100 Ophthalmic Emulsion, Placebo

Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)

Trial Locations (3)

16066

Scott & Christie and Associates, PC, Cranberry Township

91204

Global Research Management, Inc., Glendale

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors
lead

Skye Bioscience, Inc.

INDUSTRY

NCT06144918 - Phase 2, Placebo-Controlled, Study Assessing the Safety and Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Patients With Elevated Eye Pressure | Biotech Hunter | Biotech Hunter